PGmax™ tests
PGmax tests are broad panels of more than 300 genes that are analyzed based on provided patient indications with only applicable variants being reported. These tests include exome-wide copy number variant (CNV) or genome-wide structural variant (SV)—depending on which platform you choose—for the robust testing you need.
What PGmax tests offer
PGmax tests are smaller and more focused than whole exome sequencing (WES) or whole genome sequencing (WGS) tests but larger than the standard panel. Here’s why that matters.
Cost Effective
Lower price than WES and WGS
Timely turnaround
Standard 2- to 4-week TAT* with STAT options available
Phenotype-driven analysis
Patient's clinical notes used for tailored, individual insights
Cost Effective
Lower price than WES and WGS
Timely turnaround
Standard 2- to 4-week TAT* with STAT options available
Phenotype-driven analysis
Patient's clinical notes used for tailored, individual insights
Broad testing
Comprehensive PGmax tests can catch what a smaller panel might miss
Platform options
Available on exome-based and genome-based platforms
PGmax tests across key clinical areas
Broad genetic testing informed by patient phenotype
PGmax tests bridge the gap between traditional gene panels and whole exome or genome sequencing, combining broad genetic analysis with focused, phenotype-driven interpretation.
Available on exome-based and genome-based platforms, PGmax tests evaluate hundreds to thousands of clinically relevant genes while delivering actionable results for clinicians and patients.
Need help selecting the right test?
Our team of experts can help determine whether a PGmax test is the best fit for your patient.